# Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT00990249** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Allogeneic Haematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Clofarabine
- **DRUG:** Thymoglobulin
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00990249
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990249, "Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00990249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*